Buprenorphine Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Occurrence of Chronic Pain Disorders
- Rising Healthcare Expenditure in Developed Nations
Challenges
- Adverse Health Effects Associated with the Use of Buprenorphine
Buprenorphine Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
14.4% |
|
Base Year Market Size (2024) |
USD 6.22 billion |
|
Forecast Year Market Size (2037) |
USD 35.75 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of buprenorphine is assessed at USD 6.98 billion.
Buprenorphine Market size was valued at USD 6.22 billion in 2024 and is expected to reach USD 35.75 billion by 2037, expanding at around 14.4% CAGR during the forecast period i.e., between 2025-2037.
North America industry is set to account for largest revenue share by 2037, on the back of strong presence of market players and growing percentage of the population suffering from opioid dependency in the region.
The major players in the market are The Siegfried Group, LLP, Johnson Matthey Group, Purdue Pharma LP, Pharmaforce Inc., Hikma Pharmaceuticals PLC, and others.
